stockrowGSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
- Revenue
- +3.75%
- EPS
- −14.7%
- Free cash flow
- +62.4%
- Total debt
- +33.2%
Quarter to September 2026, against a year earlier
Follow GSK
Alert me
GSK PLC Sponsored ADR (GSK) Free cash flow margin
GSK PLC Sponsored ADR's free cash flow margin over the twelve months to 30 September 2026 was 19.7%, up 4.7 percentage points from fiscal 2025 (15.0%). Over the past ten years it has ranged from 4.08% (fiscal 2015) to 22.9% (fiscal 2018); the current reading is higher than 36% of that period. That is above the Drug Manufacturers General industry median of 18.5% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 15.0% | 2.97 |
| FY2024 | 12.0% | (2.71) |
| FY2023 | 14.7% | (3.99) |
| FY2022 | 18.7% | 1.31 |
| FY2021 | 17.4% | (4.67) |
| FY2020 | 22.1% | 3.24 |
| FY2019 | 18.8% | (4.04) |
| FY2018 | 22.9% | 6.16 |
| FY2017 | 16.7% | 0.48 |
| FY2016 | 16.2% | 12.15 |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| GILD Gilead Sciences, Inc. compare | 44.5% |
| SNY Sanofi compare | 40.3% |
| AMGN Amgen Inc. compare | 24.6% |
| GSK GSK PLC Sponsored ADR | 19.7% |
| BMY Bristol Myers Squibb Company compare | 18.6% |
| PFE Pfizer Inc. compare | 18.5% |
| BIIB Biogen Inc. compare | 16.5% |
| NVO Novo Nordisk A/S compare | 14.8% |
| AZN AstraZeneca PLC compare | 10.2% |
| Drug Manufacturers General industry median | 18.5% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on GSK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement